Imaging Equipment Ltd has launched the IGEA Cliniporator in the UK for the treatment of recurrent skin tumours and metastatic skin tumours. It is particularly successful in recurrent breast tumours.
Electrochemotherapy is a new local therapeutic approach for the control and treatment of cutaneous and subcutaneous tumours. Electrochemotherapy combines two effects; administration of a low dose of the drug (bleomycin or cisplatin) and electroporation of cell membranes. Electroporation is a physical phenomenon enabling, by means of short intense electric pulses, to increase the permeability of cell membranes. This increased permeability allows non permeant or poorly permeant drugs to enter the cytosol and increase their intrinsic antitumour efficacy.
Electrochemotherapy is an elective treatment which has few side effects and can be repeated. It preserves the organs’ functioning and the surrounding healthy tissue. It is comfortable for the patient and allows immediate recovery.
There are three different electrodes that have been developed in order to treat different tumoral areas by means of an appropriate distribution of the electric field applied.
Ø Plate electrodes for superficial tumours and the corresponding electric field distribution.
Ø Needle electrodes, parallel row array for small deep tumours and the corresponding electric field distribution.
Ø Needle electrodes, hexagonal array, for big deep tumours and the electric field distribution between every couple of needles.
Nick Stevens Managing Director, Imaging Equipment Ltd is quoted as saying;
“Electrochemotherapy allows very powerful chemotherapy agents to be injected directly into the skin tumours and over 85% of tumours respond successfully, regardless of histology. This can bring enormous reduction in pain and discomfort to patients with ulcerating or bleeding skin lesions, or skin lesions in places which are difficult to access or treat in a single surgical session”
“-------------------------------------------------“
Purchase and rental options are both available.
Posted on 11 Jun 2007
‹ Back to News |
